Recce Pharmaceuticals Ltd
RECEF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $563 | $6,946 | $0 | $2,381 |
| % Growth | -91.9% | – | -100% | – |
| Cost of Goods Sold | $2,056 | $8,391 | $173 | $193 |
| Gross Profit | -$1,493 | -$1,444 | -$173 | $2,188 |
| % Margin | -265.4% | -20.8% | – | 91.9% |
| R&D Expenses | $1,944 | $8,299 | $0 | $4,723 |
| G&A Expenses | $7,420 | $1,042 | $1,019 | $1,019 |
| SG&A Expenses | $4,991 | $4,709 | $12,270 | $9,414 |
| Sales & Mktg Exp. | -$2,429 | $3,667 | $1,241 | $8,396 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6,935 | $13,008 | $12,270 | $9,414 |
| Operating Income | -$8,428 | -$14,453 | -$12,444 | -$9,608 |
| % Margin | -1,498.2% | -208.1% | – | -403.4% |
| Other Income/Exp. Net | -$5,265 | -$21 | -$381 | -$135 |
| Pre-Tax Income | -$13,693 | -$14,473 | -$12,825 | -$9,743 |
| Tax Expense | $0 | -$6,738 | -$2,625 | -$2,281 |
| Net Income | -$13,693 | -$7,735 | -$10,200 | -$7,462 |
| % Margin | -2,434.2% | -111.4% | – | -313.3% |
| EPS | -0.056 | -0.034 | -0.05 | -0.042 |
| % Growth | -65.4% | 32.4% | -20.2% | – |
| EPS Diluted | -0.056 | -0.034 | -0.05 | -0.042 |
| Weighted Avg Shares Out | 244,954 | 228,858 | 203,987 | 179,371 |
| Weighted Avg Shares Out Dil | 244,953 | 228,997 | 203,987 | 179,371 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $148 | $39 |
| Interest Expense | $0 | $660 | $572 | $274 |
| Depreciation & Amortization | $35 | $86 | $173 | $193 |
| EBITDA | -$13,296 | -$6,988 | -$12,079 | -$9,275 |
| % Margin | -2,363.7% | -100.6% | – | -389.5% |